Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia
Current conventional treatment strategies for glioblastoma (GBM) have limited efficacy due to the rapid development of resistance to temozolomide (TMZ). It is particularly urgent to develop novel therapeutic strategies that can overcome TMZ resistance and provide patients with better prognoses. Here...
Gespeichert in:
| Veröffentlicht in: | Brain tumor pathology 2021-07, Vol.38 (3), p.189-200 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 200 |
|---|---|
| container_issue | 3 |
| container_start_page | 189 |
| container_title | Brain tumor pathology |
| container_volume | 38 |
| creator | Dang, Weiqi Xiao, Jingfang Ma, Qinghua Miao, Jingya Cao, Mianfu Chen, Lu Shi, Yu Yao, Xiaohong Yu, Shichang Liu, Xindong Cui, Youhong Zhang, Xia Bian, Xiuwu |
| description | Current conventional treatment strategies for glioblastoma (GBM) have limited efficacy due to the rapid development of resistance to temozolomide (TMZ). It is particularly urgent to develop novel therapeutic strategies that can overcome TMZ resistance and provide patients with better prognoses. Here, a TMZ-resistant GBM cell strain and a mouse model of TMZ resistance are established as valuable tools to explore novel therapeutic strategies against TMZ resistance. Experimentally, p38MAPK inhibitor reduces the accumulation of F4/80
+
/CD11b
+
macrophages/microglia in glioma and prolongs the survivals of glioma-bearing mice. Glioma-associated macrophages/microglia have a significanct expression of PD-L1. p38MAPK inhibitor in combination with PD-L1 antibody can effectively prolongs the survivals of TMZ-resistant GBM-bearing hosts, and differentially reduces the accumulation of circulating monocytes-derived tumor-associated macrophages and PD-L1 abundances of resident glioma-associated microglia. This combination therapy could be a treatment option for patients at the recurrence or chronic TMZ maintenance stages. A clinical study to confirm the safety and effectiveness of this combination therapy is warranted. |
| doi_str_mv | 10.1007/s10014-021-00404-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2549206670</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2918091971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-51867d57ac379bdc7b5a245c29d64bfd43fe9703b34be6dffad7536d2f8f4a983</originalsourceid><addsrcrecordid>eNp9Uk2P0zAQjRBILIU_wMkSFy4GO3bi5LhaPkURewCJW-TE43ZWSRxst1D-Ohem26JFHLjYHvu9N8-jVxRPpXghhTAvE61Sc1FKLoQWmqt7xYVsaslVY77ep7NWihvVNg-LRyndEEgLIy-KX1dh6nG2GcPMgmeLatjHy-sPDOct9phDZN8xb9n1K76WzM4Z--AODLyHIeMexgNbYhjDvEks7eIe93ZMR6EMU_hJDxM64BESpkxsthkxTJb3YCPOGzbhAGyPlkVwu-GPCZw9jjmSKYKcGTalMKDN4NhkhxiWrd1AIkfu7A1-LNQm3UrM7NjRwV3Dv-lIdLq2j4sHntzCk_O-Kr68ef356h1ff3r7_upyzQdl6swrmqNxlbFUtr0bTF_ZUldD2bpa995p5aE1QvVK91A7760zlapd6RuvbduoVfH8pEuT-raDlLsJ0wDjaGcIu9SVlW5LUdeksSqe_QO9Cbs4k7uubGUjWtkaSajyhKKPpBTBd0vEycZDJ0V3zEN3ykNHeehu89ApIqkTKS3H0UO8k_4P6zdgIL93</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918091971</pqid></control><display><type>article</type><title>Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia</title><source>ProQuest Central (Alumni Edition)</source><source>ProQuest Central UK/Ireland</source><source>SpringerLink Journals - AutoHoldings</source><source>ProQuest Central</source><creator>Dang, Weiqi ; Xiao, Jingfang ; Ma, Qinghua ; Miao, Jingya ; Cao, Mianfu ; Chen, Lu ; Shi, Yu ; Yao, Xiaohong ; Yu, Shichang ; Liu, Xindong ; Cui, Youhong ; Zhang, Xia ; Bian, Xiuwu</creator><creatorcontrib>Dang, Weiqi ; Xiao, Jingfang ; Ma, Qinghua ; Miao, Jingya ; Cao, Mianfu ; Chen, Lu ; Shi, Yu ; Yao, Xiaohong ; Yu, Shichang ; Liu, Xindong ; Cui, Youhong ; Zhang, Xia ; Bian, Xiuwu</creatorcontrib><description>Current conventional treatment strategies for glioblastoma (GBM) have limited efficacy due to the rapid development of resistance to temozolomide (TMZ). It is particularly urgent to develop novel therapeutic strategies that can overcome TMZ resistance and provide patients with better prognoses. Here, a TMZ-resistant GBM cell strain and a mouse model of TMZ resistance are established as valuable tools to explore novel therapeutic strategies against TMZ resistance. Experimentally, p38MAPK inhibitor reduces the accumulation of F4/80
+
/CD11b
+
macrophages/microglia in glioma and prolongs the survivals of glioma-bearing mice. Glioma-associated macrophages/microglia have a significanct expression of PD-L1. p38MAPK inhibitor in combination with PD-L1 antibody can effectively prolongs the survivals of TMZ-resistant GBM-bearing hosts, and differentially reduces the accumulation of circulating monocytes-derived tumor-associated macrophages and PD-L1 abundances of resident glioma-associated microglia. This combination therapy could be a treatment option for patients at the recurrence or chronic TMZ maintenance stages. A clinical study to confirm the safety and effectiveness of this combination therapy is warranted.</description><identifier>ISSN: 1433-7398</identifier><identifier>EISSN: 1861-387X</identifier><identifier>DOI: 10.1007/s10014-021-00404-3</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Antibodies ; Cancer Research ; Cells ; Flow cytometry ; Glioma ; Immunotherapy ; Laboratory animals ; Medicine ; Medicine & Public Health ; Mutation ; Neurology ; Neurosurgery ; Oncology ; Original Article ; Pathology ; Software ; Tumors</subject><ispartof>Brain tumor pathology, 2021-07, Vol.38 (3), p.189-200</ispartof><rights>The Japan Society of Brain Tumor Pathology 2021</rights><rights>The Japan Society of Brain Tumor Pathology 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-51867d57ac379bdc7b5a245c29d64bfd43fe9703b34be6dffad7536d2f8f4a983</citedby><cites>FETCH-LOGICAL-c376t-51867d57ac379bdc7b5a245c29d64bfd43fe9703b34be6dffad7536d2f8f4a983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10014-021-00404-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2918091971?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,21387,21388,27923,27924,33529,33530,33743,33744,41487,42556,43658,43804,51318,64384,64386,64388,72240</link.rule.ids></links><search><creatorcontrib>Dang, Weiqi</creatorcontrib><creatorcontrib>Xiao, Jingfang</creatorcontrib><creatorcontrib>Ma, Qinghua</creatorcontrib><creatorcontrib>Miao, Jingya</creatorcontrib><creatorcontrib>Cao, Mianfu</creatorcontrib><creatorcontrib>Chen, Lu</creatorcontrib><creatorcontrib>Shi, Yu</creatorcontrib><creatorcontrib>Yao, Xiaohong</creatorcontrib><creatorcontrib>Yu, Shichang</creatorcontrib><creatorcontrib>Liu, Xindong</creatorcontrib><creatorcontrib>Cui, Youhong</creatorcontrib><creatorcontrib>Zhang, Xia</creatorcontrib><creatorcontrib>Bian, Xiuwu</creatorcontrib><title>Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia</title><title>Brain tumor pathology</title><addtitle>Brain Tumor Pathol</addtitle><description>Current conventional treatment strategies for glioblastoma (GBM) have limited efficacy due to the rapid development of resistance to temozolomide (TMZ). It is particularly urgent to develop novel therapeutic strategies that can overcome TMZ resistance and provide patients with better prognoses. Here, a TMZ-resistant GBM cell strain and a mouse model of TMZ resistance are established as valuable tools to explore novel therapeutic strategies against TMZ resistance. Experimentally, p38MAPK inhibitor reduces the accumulation of F4/80
+
/CD11b
+
macrophages/microglia in glioma and prolongs the survivals of glioma-bearing mice. Glioma-associated macrophages/microglia have a significanct expression of PD-L1. p38MAPK inhibitor in combination with PD-L1 antibody can effectively prolongs the survivals of TMZ-resistant GBM-bearing hosts, and differentially reduces the accumulation of circulating monocytes-derived tumor-associated macrophages and PD-L1 abundances of resident glioma-associated microglia. This combination therapy could be a treatment option for patients at the recurrence or chronic TMZ maintenance stages. A clinical study to confirm the safety and effectiveness of this combination therapy is warranted.</description><subject>Antibodies</subject><subject>Cancer Research</subject><subject>Cells</subject><subject>Flow cytometry</subject><subject>Glioma</subject><subject>Immunotherapy</subject><subject>Laboratory animals</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mutation</subject><subject>Neurology</subject><subject>Neurosurgery</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pathology</subject><subject>Software</subject><subject>Tumors</subject><issn>1433-7398</issn><issn>1861-387X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9Uk2P0zAQjRBILIU_wMkSFy4GO3bi5LhaPkURewCJW-TE43ZWSRxst1D-Ohem26JFHLjYHvu9N8-jVxRPpXghhTAvE61Sc1FKLoQWmqt7xYVsaslVY77ep7NWihvVNg-LRyndEEgLIy-KX1dh6nG2GcPMgmeLatjHy-sPDOct9phDZN8xb9n1K76WzM4Z--AODLyHIeMexgNbYhjDvEks7eIe93ZMR6EMU_hJDxM64BESpkxsthkxTJb3YCPOGzbhAGyPlkVwu-GPCZw9jjmSKYKcGTalMKDN4NhkhxiWrd1AIkfu7A1-LNQm3UrM7NjRwV3Dv-lIdLq2j4sHntzCk_O-Kr68ef356h1ff3r7_upyzQdl6swrmqNxlbFUtr0bTF_ZUldD2bpa995p5aE1QvVK91A7760zlapd6RuvbduoVfH8pEuT-raDlLsJ0wDjaGcIu9SVlW5LUdeksSqe_QO9Cbs4k7uubGUjWtkaSajyhKKPpBTBd0vEycZDJ0V3zEN3ykNHeehu89ApIqkTKS3H0UO8k_4P6zdgIL93</recordid><startdate>20210701</startdate><enddate>20210701</enddate><creator>Dang, Weiqi</creator><creator>Xiao, Jingfang</creator><creator>Ma, Qinghua</creator><creator>Miao, Jingya</creator><creator>Cao, Mianfu</creator><creator>Chen, Lu</creator><creator>Shi, Yu</creator><creator>Yao, Xiaohong</creator><creator>Yu, Shichang</creator><creator>Liu, Xindong</creator><creator>Cui, Youhong</creator><creator>Zhang, Xia</creator><creator>Bian, Xiuwu</creator><general>Springer Singapore</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>7X8</scope></search><sort><creationdate>20210701</creationdate><title>Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia</title><author>Dang, Weiqi ; Xiao, Jingfang ; Ma, Qinghua ; Miao, Jingya ; Cao, Mianfu ; Chen, Lu ; Shi, Yu ; Yao, Xiaohong ; Yu, Shichang ; Liu, Xindong ; Cui, Youhong ; Zhang, Xia ; Bian, Xiuwu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-51867d57ac379bdc7b5a245c29d64bfd43fe9703b34be6dffad7536d2f8f4a983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Cancer Research</topic><topic>Cells</topic><topic>Flow cytometry</topic><topic>Glioma</topic><topic>Immunotherapy</topic><topic>Laboratory animals</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mutation</topic><topic>Neurology</topic><topic>Neurosurgery</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pathology</topic><topic>Software</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dang, Weiqi</creatorcontrib><creatorcontrib>Xiao, Jingfang</creatorcontrib><creatorcontrib>Ma, Qinghua</creatorcontrib><creatorcontrib>Miao, Jingya</creatorcontrib><creatorcontrib>Cao, Mianfu</creatorcontrib><creatorcontrib>Chen, Lu</creatorcontrib><creatorcontrib>Shi, Yu</creatorcontrib><creatorcontrib>Yao, Xiaohong</creatorcontrib><creatorcontrib>Yu, Shichang</creatorcontrib><creatorcontrib>Liu, Xindong</creatorcontrib><creatorcontrib>Cui, Youhong</creatorcontrib><creatorcontrib>Zhang, Xia</creatorcontrib><creatorcontrib>Bian, Xiuwu</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>MEDLINE - Academic</collection><jtitle>Brain tumor pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dang, Weiqi</au><au>Xiao, Jingfang</au><au>Ma, Qinghua</au><au>Miao, Jingya</au><au>Cao, Mianfu</au><au>Chen, Lu</au><au>Shi, Yu</au><au>Yao, Xiaohong</au><au>Yu, Shichang</au><au>Liu, Xindong</au><au>Cui, Youhong</au><au>Zhang, Xia</au><au>Bian, Xiuwu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia</atitle><jtitle>Brain tumor pathology</jtitle><stitle>Brain Tumor Pathol</stitle><date>2021-07-01</date><risdate>2021</risdate><volume>38</volume><issue>3</issue><spage>189</spage><epage>200</epage><pages>189-200</pages><issn>1433-7398</issn><eissn>1861-387X</eissn><abstract>Current conventional treatment strategies for glioblastoma (GBM) have limited efficacy due to the rapid development of resistance to temozolomide (TMZ). It is particularly urgent to develop novel therapeutic strategies that can overcome TMZ resistance and provide patients with better prognoses. Here, a TMZ-resistant GBM cell strain and a mouse model of TMZ resistance are established as valuable tools to explore novel therapeutic strategies against TMZ resistance. Experimentally, p38MAPK inhibitor reduces the accumulation of F4/80
+
/CD11b
+
macrophages/microglia in glioma and prolongs the survivals of glioma-bearing mice. Glioma-associated macrophages/microglia have a significanct expression of PD-L1. p38MAPK inhibitor in combination with PD-L1 antibody can effectively prolongs the survivals of TMZ-resistant GBM-bearing hosts, and differentially reduces the accumulation of circulating monocytes-derived tumor-associated macrophages and PD-L1 abundances of resident glioma-associated microglia. This combination therapy could be a treatment option for patients at the recurrence or chronic TMZ maintenance stages. A clinical study to confirm the safety and effectiveness of this combination therapy is warranted.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><doi>10.1007/s10014-021-00404-3</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1433-7398 |
| ispartof | Brain tumor pathology, 2021-07, Vol.38 (3), p.189-200 |
| issn | 1433-7398 1861-387X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2549206670 |
| source | ProQuest Central (Alumni Edition); ProQuest Central UK/Ireland; SpringerLink Journals - AutoHoldings; ProQuest Central |
| subjects | Antibodies Cancer Research Cells Flow cytometry Glioma Immunotherapy Laboratory animals Medicine Medicine & Public Health Mutation Neurology Neurosurgery Oncology Original Article Pathology Software Tumors |
| title | Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T01%3A55%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20of%20p38%20MAPK%20inhibitor%20with%20PD-L1%20antibody%20effectively%20prolongs%20survivals%20of%20temozolomide-resistant%20glioma-bearing%20mice%20via%20reduction%20of%20infiltrating%20glioma-associated%20macrophages%20and%20PD-L1%20expression%20on%20resident%20glioma-associated%20microglia&rft.jtitle=Brain%20tumor%20pathology&rft.au=Dang,%20Weiqi&rft.date=2021-07-01&rft.volume=38&rft.issue=3&rft.spage=189&rft.epage=200&rft.pages=189-200&rft.issn=1433-7398&rft.eissn=1861-387X&rft_id=info:doi/10.1007/s10014-021-00404-3&rft_dat=%3Cproquest_cross%3E2918091971%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2918091971&rft_id=info:pmid/&rfr_iscdi=true |